A new clinical trial with oleocanthal oleacein dietary intervention with the Governor Extra virgin olive oil

 

The study The Effect of Dietary Intervention With High-Oleocanthal and Oleacein Olive Oil in Patients With Early-Stage Chronic Lymphocytic Leukemia: A Pilot Randomised Trial

The international, prestigious scientific journal Frontiers in Oncology, published an article on on Friday 21 January 2022 with the results of the research entitled:

This a historic day for research, Corfiot and Greek olive oil and a unique moment for our Governor.

The aim of this pilot study was to test if patients at early stage of chronic lymphocytic leukemia (CLL) could adhere to and tolerate a dietary intervention with high Oleocanthal and Oleacein extra virgin olive oil (EVOO) and if this intervention could lead to any changes in markers related to the disease.

Dr. Prokopios Magiatis and Dr. Eleni Melliou initiated the study after receiving feedback from people suffering with CLL claiming their white blood cell count declined after beginning to consume olive oil rich in oleocanthal and oleacein.

Conclusions. This is the first clinical trial that we were able to show that oral administration of a daily dose of 25 mg oleocanthal and oleacein through the consumption of 40 mL of Extra Virgin Olive Oil for a six-month period could be beneficial for CLL patients, reducing white blood cell count, inducing the apoptosis of their cancer cells, and improving the metabolism of the patients.

This is very exciting and promising news which paves the way for further larger scale studies.

“It is an honour that the Governor was chosen for this research. We continue in high sense of responsibility as we did since the start.” The Dafnis Family

Please see the link  for full details https://www.frontiersin.org/articles/10.3389/fonc.2021.810249/full

Share this post